TY - JOUR T1 -治疗阻塞性睡眠呼吸暂停期间所需的鼻持续气道正压水平JF -欧洲呼吸杂志JO - Eur Respir J SP - 1776 LP - 1781 VL - 7 IS - 10 AU - Series, F AU - Marc, I AU - Cormier, Y AU - La Forge，鼻持续气道正压通气(NCPAP)治疗期间阻塞性睡眠相关呼吸障碍严重程度的改善可以解释所需NCPAP水平随时间的降低。本研究的目的是前瞻性量化睡眠呼吸暂停-低通气综合征(SAHS)患者所需的NCPAP水平随使用时间的变化。对40例睡眠呼吸暂停-低通气患者在NCPAP治疗前和治疗期间进行评估。有效的NCPAP水平被定义为在所有睡眠阶段和睡眠姿势中消除窒息和催眠事件以及打鼾的正压水平。该压力水平在基线诊断性睡眠研究后2周内确定。在NCPAP治疗2个月(n = 40)、8个月(n = 40)和20个月(n = 24)后进行NCPAP和NCPAP滴定的睡眠研究。初始有效NCPAP水平为9.6 +/- 0.4 cmH2O。2个月、8个月和20个月后分别逐渐下降至8.8 +/- 0.4、7.9 +/- 0.4和7.7 +/- 0.5;前三个NCPAP夜晚之间的差异非常显著。 There was a poor relationship between the changes in the effective NCPAP and changes in weight recorded at the different visits. There was a weak negative relationship between the changes in NCPAP and the previous NCPAP level. In 13 patients, the apnoea-hypopnoea index (AHI) remained > 10 n.h-1 at the first NCPAP trial because the effective NCPAP level was not tolerated. Despite a suboptimal NCPAP level, their sleep architecture improved, and they all reported a subjective improvement in diurnal hypersomnolence.(ABSTRACT TRUNCATED AT 250 WORDS) ER -